SEC Form 3 · accession 0001209191-17-042192
Dova Pharmaceuticals Inc. · DOVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Douglas Blankenship
Officer — Chief Financial Officer
Period of report
Jun 28, 2017
Accepted (ET)
Jun 28, 2017 · 8:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001685071
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $3.73 | holding | — | — | — | — | Mar 27, 2027 | Common Stock | 228,525 | — | D |
Explanation of responses
- F1The option shall vest over a period of four years as follows: (i) 25% of the total shares subject to the option shall vest on March 1, 2018, and (ii) 1/48th of total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service with the Issuer as of each such date. The option allows for early exercise, subject to the Issuer's repurchase option, with respect to any unvested shares of Common Stock.
Remarks
Exhibit List - Exhibit 24 - Power of Attorney